Overview Dividends

(ITGR) Integer Holdings - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US45826H1095

Medical Devices, Cardiac Rhythm, Neuromodulation, Batteries, Orthopedics

Health Care Equipment
Market Cap in USD: 2,758m

IPO / Inception: 2000-09-29
Return 12m vs S&P 500: -50.3%

EPS (Earnings per Share)

EPS CAGR: 17.11%
EPS Trend: 88.1%

Last SUE: 1.91
Qual. Beats: 1

Revenue

Rev. CAGR: 11.30%
Rev. Trend: 96.8%

Last SUE: 0.07
Qual. Beats: 0

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	29.7%
Value at Risk 5%th	42.9%
Relative Tail Risk	-12.26%

Reward TTM
Sharpe Ratio	-1.11
Alpha	-54.29
CAGR/Max DD	0.08

Character TTM
Hurst Exponent	0.332
Beta	0.725
Beta Downside	0.575

Drawdowns 3y
Max DD	56.14%
Mean DD	10.92%
Median DD	5.25%

Description: ITGR Integer Holdings November 08, 2025

Integer Holdings Corp (NYSE: ITGR) is a contract development and manufacturing organization (CDMO) that produces a broad portfolio of medical devices for OEM customers, covering cardiac rhythm management, neuromodulation, orthopedics, vascular, and portable-medical markets. Its operations span the United States, Puerto Rico, Costa Rica, and other international sites, serving multinational manufacturers and their subsidiaries.

Key performance indicators from the most recent fiscal year (2023) show revenue of roughly $2.2 billion, with an operating margin of about 5 % and a free-cash-flow conversion rate near 70 %. The cardiac rhythm management segment, the largest contributor, grew ~6 % YoY, reflecting continued demand for implantable pacemakers and defibrillators amid an aging U.S. population and expanding indications for heart-failure therapy.

Sector-level drivers that materially affect Integer include (1) the U.S. healthcare spending outlook, projected to rise 4-5 % annually through 2027, which sustains demand for high-margin implantable devices; (2) supply-chain pressures on specialty components such as non-rechargeable batteries, where lead times have widened 20-30 % in 2024, potentially compressing contract pricing; and (3) regulatory trends, notably the FDA’s emphasis on post-market surveillance, which can increase OEM reliance on CDMOs for compliance-ready manufacturing.

For analysts seeking a deeper quantitative view of Integer’s valuation dynamics, a quick look at ValueRay’s proprietary risk-adjusted return metrics can surface hidden upside or downside factors worth exploring.

Piotroski VR‑10 (Strict, 0-10) 4.5

Net Income (86.9m TTM) > 0 and > 6% of Revenue (6% = 109.9m TTM)

FCFTA 0.05 (>2.0%) and ΔFCFTA 2.54pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 31.04% (prev 30.37%; Δ 0.67pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.06 (>3.0%) and CFO 204.0m > Net Income 86.9m (YES >=105%, WARN >=100%)

Net Debt (1.25b) to EBITDA (356.3m) ratio: 3.51 <= 3.0 (WARN <= 3.5)

Current Ratio 3.71 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (35.6m) change vs 12m ago -0.51% (target <= -2.0% for YES)

Gross Margin 26.99% (prev 27.15%; Δ -0.16pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 55.78% (prev 52.77%; Δ 3.01pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 5.17 (EBITDA TTM 356.3m / Interest Expense TTM 45.2m) >= 6 (WARN >= 3)

Altman Z'' 3.12

(A) 0.17 = (Total Current Assets 778.1m - Total Current Liabilities 209.8m) / Total Assets 3.40b

(B) 0.28 = Retained Earnings (Balance) 945.4m / Total Assets 3.40b

(D) 0.61 = Book Value of Equity 1.01b / Total Liabilities 1.65b

Total Rating: 3.12 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 67.14

1. Piotroski 4.50pt

2. FCF Yield 4.13%

3. FCF Margin 9.04%

4. Debt/Equity 0.75

5. Debt/Ebitda 3.51

6. ROIC - WACC (= 1.05)%

7. RoE 5.21%

8. Rev. Trend 96.83%

9. EPS Trend 88.12%

What is the price of ITGR shares?

As of December 30, 2025, the stock is trading at USD 78.53 with a total of 365,999 shares traded.
Over the past week, the price has changed by -0.88%, over one month by +9.45%, over three months by -22.34% and over the past year by -41.21%.

Is ITGR a buy, sell or hold?

Integer Holdings has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy ITGR.

Strong Buy: 7
Buy: 2
Hold: 1
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the ITGR price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	85.6	9%
Analysts Target Price	85.6	9%
ValueRay Target Price	74.1	-5.7%

ITGR Fundamental Data Overview December 26, 2025

Market Cap USD = 2.76b (2.76b USD * 1.0 USD.USD)
P/E Trailing = 32.3909
P/E Forward = 8.726
P/S = 1.5062
P/B = 1.5797
P/EG = 0.349
Beta = 0.815
Revenue TTM = 1.83b USD
EBIT TTM = 233.5m USD
EBITDA TTM = 356.3m USD
Long Term Debt = 1.19b USD (from longTermDebt, last quarter)
Short Term Debt = 9.12m USD (from shortTermDebt, last quarter)
Debt = 1.31b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.25b USD (from netDebt column, last quarter)
Enterprise Value = 4.01b USD (2.76b + Debt 1.31b - CCE 58.9m)
Interest Coverage Ratio = 5.17 (Ebit TTM 233.5m / Interest Expense TTM 45.2m)
FCF Yield = 4.13% (FCF TTM 165.5m / Enterprise Value 4.01b)
FCF Margin = 9.04% (FCF TTM 165.5m / Revenue TTM 1.83b)
Net Margin = 4.75% (Net Income TTM 86.9m / Revenue TTM 1.83b)
Gross Margin = 26.99% ((Revenue TTM 1.83b - Cost of Revenue TTM 1.34b) / Revenue TTM)
Gross Margin QoQ = 26.98% (prev 27.41%)
Tobins Q-Ratio = 1.18 (Enterprise Value 4.01b / Total Assets 3.40b)
Interest Expense / Debt = 0.71% (Interest Expense 9.37m / Debt 1.31b)
Taxrate = 13.73% (6.31m / 46.0m)
NOPAT = 201.5m (EBIT 233.5m * (1 - 13.73%))
Current Ratio = 3.71 (Total Current Assets 778.1m / Total Current Liabilities 209.8m)
Debt / Equity = 0.75 (Debt 1.31b / totalStockholderEquity, last quarter 1.75b)
Debt / EBITDA = 3.51 (Net Debt 1.25b / EBITDA 356.3m)
Debt / FCF = 7.56 (Net Debt 1.25b / FCF TTM 165.5m)
Total Stockholder Equity = 1.67b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.56% (Net Income 86.9m / Total Assets 3.40b)
RoE = 5.21% (Net Income TTM 86.9m / Total Stockholder Equity 1.67b)
RoCE = 8.16% (EBIT 233.5m / Capital Employed (Equity 1.67b + L.T.Debt 1.19b))
RoIC = 7.13% (NOPAT 201.5m / Invested Capital 2.82b)
WACC = 6.09% (E(2.76b)/V(4.07b) * Re(8.69%) + D(1.31b)/V(4.07b) * Rd(0.71%) * (1-Tc(0.14)))
Discount Rate = 8.69% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 2.36%
[DCF Debug] Terminal Value 79.37% ; FCFE base≈128.9m ; Y1≈159.0m ; Y5≈271.3m
Fair Price DCF = 116.4 (DCF Value 4.08b / Shares Outstanding 35.0m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 88.12 | EPS CAGR: 17.11% | SUE: 1.91 | # QB: 1
Revenue Correlation: 96.83 | Revenue CAGR: 11.30% | SUE: 0.07 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.35 | Chg30d=+0.003 | Revisions Net=-6 | Analysts=6
EPS next Year (2026-12-31): EPS=6.30 | Chg30d=-0.011 | Revisions Net=-8 | Growth EPS=-0.7% | Growth Revenue=-0.1%

Additional Sources for ITGR Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle